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Background. Hemorrhage is the second leading
cause of death in civilian trauma and the leading cause
of preventable death in military trauma. The purpose
of this study was to examine the effectiveness of
three hemostatic agents: BleedArrest, TraumaDex,
and Celox.
Materials and Methods. This was a prospective, ex-
perimental study using male Yorkshire swine. The pigs
(n[ 5 per group) were randomly assigned to one of the
following: BleedArrest, TraumaDex, Celox, or control.
Tosimulateatraumainjury, theinvestigatorsgenerated
a complex groin injury with transection of the femoral
artery and vein in all pigs. After 1 min of uncontrolled
hemorrhage, one of the hemostatic agents was poured
into the wound, followed by standard wound packing.
The control group underwent the same procedures
with the exception of the hemostatic agents. In all
groups, 5 min of direct manual pressure was applied to
the wound followed by a standard pressure dressing.
After 30 min, dressings were removed, and the amount
of bleeding was determined.
Results. There were significant differences between
theBleedArrest (mean[21.2, SD±36.6mL)TraumaDex
(mean[68,SD±103.5mL)andCelox(mean[18.l6,SD±
41.6mL) groups comparedwith Control group (mean[
230,SD±154mL) (P<0.05).However, therewerenosta-
tistically significant difference between BleedArrest,
TraumaDex, and Celox groups (P[ 0.478).
Conclusions. BleedArrest, Celox, and TraumaDex
were statistically and clinically superior at controlling
hemorrhage compared with the standard pressure
dressing in the control group. Published by Elsevier Inc.
Key Words: hemorrhage; hemorrhage control; hemo-
static agents.
INTRODUCTION
Uncontrolled hemorrhage is the second leading cause
of death in civilian trauma [1] and the leading cause of
preventable death in military trauma [1–9]. Histori-
cally, 20% of combat casualties were killed in action.
Ninety percent of those deaths occurred prior to arrival
at a field hospital with exsanguination as the leading
cause of death [5]. Of the soldiers who died from exsan-
guination in Vietnam, 40% had bleeding that may have
been controlled by a hemostatic agent [8].
If trauma victims survive the initial blood loss, they
are prone to hypothermia, coagulopathy, acidosis, in-
fection, andmultiple organ failure. These complications
result in an increase in mortality even after successful
resuscitation [1, 9–11]. Avoiding this lethal cascade
requires hemorrhage control prior to arrival at the
hospital minimizing blood loss and allowing for earlier
resuscitation [12–14, 15].
Several hemostatic agents have been investigated
over the past decade with mixed and inconclusive re-
sults [15–17, 18–21, 22, 23, 24, 25, 26–28, 29, 30, 31,
32–34]. The purpose of this study was to examine the
effectiveness of three hemostatic agents: BleedArrest,
TraumaDex, and Celox. The research question guiding
this study was as follows: Is there a statistically
1 To whom correspondence and reprint requests should be
addressed at Department of the Army, Academy of Health Sciences,
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significant difference in the amount of bleeding among
BleedArrest, TraumaDex, Celox, and the control group?
The mechanism of action of BleedArrest (Hemostasis
LLC, St. Paul,MN) is based on the absorbance of plasma
by amylopectin, a plant-based starch. The result is the
concentration of platelets and coagulation factors at
the site of injury supporting the formation of a robust
clot. Similarly, TraumaDex (Medafor Corporation,Min-
neapolis, MN) is based on a plant-based starch, referred
to asmicroporous polysaccharide hemospheres technol-
ogy. The polysaccharides act as microscopic sponges
that absorb plasma, concentrate platelets and coagula-
tion factors, and form a gel-like matrix enhancing clot
formation.
Celox (Medtrade Biopolymers, Crewe, UK, distrib-
uted in the United States by SAM Products, Portland,
OR) uses chitosan, produced by the deacetylation of chi-
tin, a polysaccharide derived from the exoskeleton of
shrimp. Chitosan is positively charged and bonds read-
ily to the negatively charged surfaces of red blood cells,
forming an adhesive complex that works independently
of clotting factors.
MATERIALS AND METHODS
This studywasaprospective, between-subjects experimental design
using a porcinemodel. The protocol was approved by the Institutional
Animal Care andUse Committee (IACUC). The animals received care
in accordancewith theAnimalWelfareAct andTheGuide for theCare
andUse of Laboratory Animals. Twentymale Yorkshire swine weigh-
ing between 70 and 89 kgwere randomly assigned (n¼ 5 per group) to
one of four groups: BleedArrest, TraumaDex, Celox, or the control
group. The rationale for using swine of this size was that they repre-
sent the average weight of the US Army soldier [35]. The swine were
observed for 3 d to ensure a good state of health, fed a standard diet,
and were NPO after midnight the day of the experiment. This study
was conducted in four phases: induction/stabilization, hemorrhage,
hemostasis, and blood loss.
Induction/Stabilization Phase
The induction phase started with an intramuscular injection of ket-
amine (20 mg/kg) and atropine (0.04 mg/kg). Subjects were placed su-
pine on a litter and transported to an operating room followed by
inhaled isoflurane (4% to 5%). After placement of an endotracheal
tube, a peripheral i.v. catheterwas inserted and the isoflurane concen-
tration was reduced to 1% to 2% for the remainder of the experiment.
The swinewere ventilatedwith a standardNarkomed anesthesiama-
chine (Dra¨ger, Telford, PA). Heart rate, electrocardiography, blood
pressure, oxygen saturation, end-tidal carbon dioxide, and rectal tem-
peratureswere continuouslymonitored for the remainder of the exper-
iment.AThermal Industries of Florida (TIF) scale,model 9010A, (SPX
Service Solutions, Owatonna, MN) was placed between the litter and
operating room table. The TIF scale is an electronic scale that mea-
sures pressure applied in pounds per square inch and is precisewithin
0.5 ounces and accurate within 0.5%. The scale was zeroed per manu-
facturer’s instructions. While manual pressure was applied to the
wound during the experiment, the scale was observed to ensure pres-
surewasmaintained at 25 pounds per square inchwithin6 0.5 ounces
to ensure continuity from subject to subject.
The left carotid arterywas cannulatedwith a 20G angio-catheter us-
ing a cut down technique.A central venous catheterwas insertedusing
amodifiedSeldinger technique forfluid volumemanagement andblood
sampling. The catheters were attached to a hemodynamic monitoring
system (Hewlett Packard, Palo Alto, CA) for continuous monitoring of
the arterial blood pressures. All catheters were continuously flushed
with 0.9% saline solution (5 mL per h) to maintain patency. Following
line placement, the NPO fluid deficit was corrected with 0.9% normal
saline, per the Holliday-Segar formula. The investigators used an acti-
vated clotting time (ACT) test to screen all subjects for coagulopathy
prior to procedures. The upper limit in this study for all subjects was
an ACT less than 150 s. One subject in the BleedArrest group was ex-
cluded and replaced because of a prolonged ACT 2.5 times greater
than the upper limit. Subjects were furthermonitored for 30min to en-
sure hemodynamic stability prior to intervention. Body temperature
was monitored via a rectal probe and maintained at greater than
36Cusing a forced air-warming blanket. A complex groin injury as de-
scribed by Alam and colleagues was generated to simulate a penetrat-
ing injury [27]. The injury includeddissection of the proximal thigh soft
tissues including the skin, quadriceps, and adductor muscles to expose
the femoral artery and vein just below the inguinal ligament. All swine
were hemodynamically stable prior to intervention.
Hemorrhage Phase
Following the 30 min stabilization period, the exposed femoral
artery and vein were transected with a scalpel blade. The swine
were allowed to hemorrhage for 1 min, simulating the response time
of a battlefield health care provider. Blood was collected by gauze, ab-
sorbent pads underneath the animals, and in a suction canister by use
of a suction tip catheter placed in the distal portion of the wound.
Hemostasis Phase
After 1 min of hemorrhage, proximal pressure was applied to the
transected femoral vessels, and 4 in. 3 4 in. gauze was used to blot
the blood from the wound per the hemostatic agent manufacturer’s
guidelines. At this time, the hemostatic agent was poured into the
wound followed by standard wound packing with a layer of petroleum
gauze and the roller gauze (Kerlix; Covidien,Mansfield,MA). The con-
trol group received proximal pressure and standard wound packing.
Firm manual pressure of 25 lbs per square inch was applied for 5 min
to the injury site as measured by the TIF scale. After 5 min, all groups
receivedaCoban (3MInc. St. Paul,MN)wrappedpressuredressing left
in place for 30min; 500mL of 6%Hextend in lactated Ringer’s solution
(Hospira, Inc., Lake Forest, IL) i.v. was administered to all subjects in
accordance with current battlefield resuscitation protocol recommen-
ded by the Committee on Tactical Combat Casualty Care.
Blood Loss Phase
After 35min of pressure on the wound (5 minmanual pressure plus
30 min with the pressure dressing), the standard pressure dressing
was removed being careful to keep the clot intact. The rationale for us-
ing the petroleum gauze was that it allowed removal of the pressure
dressing with minimal clot disruption. For the purposes of this study,
hemostasiswas defined as a clot formationwith oozing of nomore than
2% of the swine’s total blood volume over a 5 min period (w100 mL in
a 70 kg pig). Blood losswasmeasured over two time periods: the initial
injury to intervention and post-intervention to the completion of the
study. Blood loss was calculated by weighing the dressings, absorbent
pads underneath the animals, and blood suctioned from the distal por-
tion of the wound before and after transection of the femoral vessels.
RESULTS AND DISCUSSION
The minimum number of animals was used to obtain
a statistically valid result. A large effect size was
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determined for this experiment based upon previous
work by Alam and Pusateri [21, 27]. Using G-Power
3.00, an effect size of 0.6, a power of 0.80, and an a of
0.05, it was determined that a sample size of five swine
per group was needed for this study. Investigators
evaluated coagulation studies with all subjects. There
were no statistically significant differences between the
groups in reference to the amount of initial bleeding
after 1 minute (P ¼ 0.533): BleedArrest group ranged
from 615 to 730 mL (mean ¼ 671.4, SD 6 55.8 mL);
TraumaDex group ranged from 400 to 954 mL (mean ¼
739.6, SD 6 208 mL); Celox group ranged from 300 to
900 mL (mean ¼ 541.6, SD 6 243 mL); and Control
group ranged from 205 to 862 mL (mean ¼ 554.2, SD 6
305 mL). The body weights, core body temperatures,
amount of blood volume, and the amount of the initial
1 min hemorrhage were analyzed using a multivariate
ANOVA. There were no statistically significant differ-
ences between the groups (P > 0.05), indicating that
the groups were equivalent on these parameters. Blood
loss after 35 min of pressure on the wound (manual
pressure and pressure dressing) was calculated for
each group over a 5 min observation period following
removal of dressings and exposure of the formed clot.
The amount of bleeding BleedArrest group ranged from
0 to 58 mL (mean ¼ 21.2, SD 6 36.6 mL); TraumaDex
group ranged from 0 to 234 mL (mean ¼ 68, SD 6
103.5 mL); Celox group ranged from 0 to 93 mL (mean¼
18.l6, SD6 41.6mL); andControl group ranged from0 to
421 mL (mean ¼ 230, SD 6 154 mL). An ANOVA and
a least significant difference (LSD) hoc test were used
to analyze the data and indicated a significant differ-
ence between the groups (P ¼ 0.025). There were
statistically significant differences between Bleed-
Arrest and control (P ¼ 0.01; TraumaDex and control
(P ¼ 0.038); Celox and control (P ¼ 0.01). However,
there were no statistically significant differences bet-
ween BleedArrest, TraumaDex, and Celox groups (P ¼
0.478). See Table 1 for a summary of the results.
TheUSArmy’s goal is that each soldierwill carry ahe-
mostatic agent, but research needs to be conducted to
determine the most efficacious and cost effective agent.
In addition, many civilian disaster teams and first
responders are exploring the potential for using
hemostatic agents before arrival to the hospital. Pusa-
teri outlined the ideal qualities of hemostatic agents
for civilian and military use. These include (1) being
able to rapidly stop large vessel arterial and venous
bleeding within 2 min of application when applied to
an actively bleeding wound through a pool of blood; (2)
no requirement for mixing or pre-application prepara-
tion; (3) simplicity of application by wounded victim,
buddy, or medic; (4) light weight and durable; (5) long
shelf life in extreme environments; (6) safe to use
with no risk of injury to tissues or transmission of infec-
tion; and (7) inexpensive [36]. This study compared
BleedArrest, Celox, andTraumaDex against a standard
pressure dressing, the control, in a porcine model of le-
thal femoral vascular injury. A complex groin injury
was generated simulating a penetrating injury, com-
mon in combat, in an anatomical area not protected by
conventional body armor or amenable to use of a tourni-
quet. The hemostatic agents BleedArrest, TraumaDex,
and Celox were all able to rapidly control arterial and
venous bleeding. This fulfilled the first of Pusateri’s
requirements. Celox performed clinically superior to
BleedArrest and TraumaDex, and all three were statis-
tically and clinically superior at controlling hemorrhage
compared with the standard pressure dressing control
group. The hemostatic agents in this study were easy
to apply and did not require any pre-mixing. Celox is
packaged as 35 g of loose granules in a waterproof
pouch. It was easy to open and pour into the wound. In
contrast, TraumaDex comes packaged in a plastic tip-
ped applicator containing 5 g of fine powder. Investiga-
tors noted, during model development, contact of the
applicator tip with blood in the wound caused clotting
within the applicator itself. Therefore, investigators re-
moved the TraumaDex powder from the applicator,
measured it into a weighed envelope, and poured it
into the wound in the samemanner as Celox. BleedArr-
est comes packaged ina 250 g easy to open envelope. The
investigators used enough of the hemostatic agent to
completelyfill thegroin injury cavity.Themeanweights
of the hemostatic agents were as follows: BleedArrest
24.3 g, TraumaDex 24.8 g, and Celox 23.8 g. Standard
packaging of the agents in small waterproof packets al-
lows soldiers and combat medics to easily carry these
TABLE 1
Amount of Hemorrhage by Group after 35 Min
Group Range
Mean and standard deviation of
hemorrhage for 5 min Post hoc analyses
BleedArrest 0–58 mL 21 6 36.6 mL BleedArrest versus control (P ¼ 0.01)*
TraumaDex from 0 to 234 mL 68 6103.5 mL Celox versus control (P ¼ 0.01)*
Celox 0 to 93 mL 18.l6 6 41.6 mL TraumaDex versus control (P ¼ 0.038)*
Control 0 to 421 mL 230 6 154 mL BleedArrest versus Celox versus
TraumaDex (P ¼ 0.478)
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agents in pockets, backpacks, or medic bags. These
agents could also be easily used by physicians, nurses,
and ordinary citizens in providing care in the civilian
arena. Because of the nature of the products, exposure
to heat or cold does not appear to be a factor in determin-
ing shelf life. BleedArrest has a shelf life of 3 y;Celoxhas
a shelf life of 2 y; and TraumaDex for 3 y. All of the
agents are approved by the FDA. In this study, investi-
gators noted that none of the agents produced an exo-
thermic reaction when applied to the wound, and
there were no obvious signs of tissue damage. There
were concerns and reports of thermal injury to human
tissue with some first generation mineral-based hemo-
static agents [37]. Secondary to the mechanisms of ac-
tion and the sterilization of these products, none of the
agents tested carries the risk of infection per the manu-
facturers. The three hemostatic agents are relatively in-
expensive, all costing less than $30.00 for a single
application and less when the agents are bought in
bulk. Investigators used approximately five applica-
tions of TraumaDex compared with one of Celox and




and clinically superior at controlling hemorrhage com-
paredwith the standard pressure dressing in the control
group. All of these hemostatic agents are FDAapproved,
simple to use, lightweight, have a long-shelf life, demon-
strate no known risk of tissue injury, and are relatively
inexpensive. Based on this study and the requirements
outlined by Pusateri, these hemostatic agents are effec-
tive foruse in civilianandmilitary traumamanagement.
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